Health outcomes and cost–effectiveness of certolizumab pegol in the treatment of Crohn’s disease

References

• Loftus RV. Clinical epidemiology of inflammatory bowel disease: incidence. prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US Population. Dig Dis Sci 2013;58(2):519-25
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5(12):1424-9
   PubMed Web of Science ®Google Scholar
• Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24(2):319-28
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Tuskey A, Dassopoulos T, et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 2007;13(12):1529-35
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Loftus EV, Harmsen WS, et al. Cumulative incidence of and risk factors for major abdominal surgery in a population-based cohort of Crohn’s disease. Gastroenterol 2010;138(5 Suppl 1):S-199
   Google Scholar
• Sonnenberg A, Chang J. Time trends of physician visits for Crohn’s disease and ulcerative colitis in the United States, 1960-2006. Inflamm Bowel Dis 2008;14(2):249-52
   PubMedGoogle Scholar
• Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med 2008;50(11):1261-72
   PubMed Web of Science ®Google Scholar
• Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131(3):719-28
   PubMed Web of Science ®Google Scholar
• Buchanan J, Wordsworth S, Ahmad T, et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis 2001;5(4):301-16
   Google Scholar
• Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis 2007;1(1):10-20
   PubMed Web of Science ®Google Scholar
• Engelmann G, Erhard D, Petersen M, et al. Health-related quality of life in adolescents with inflammatory bowel disease depends on disease activity and psychiatric comorbidity. Child Psychiatry Hum Dev 2014. [Epub ahead of print]
   Google Scholar
• Danese S. Adalimumab in ulcerative colitis: ready for prime time. Dig Liver Dis 2013;45(1):8-13
   PubMedGoogle Scholar
• Harrison J, Hanauer SB. Medical treatment of Crohn’s disease. Gastroenterol Clin North Am 2002;31(1):167-84
   PubMedGoogle Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104(2):465-83
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):935-9
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex 2006;71(3):351-401
   PubMedGoogle Scholar
• Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterol 2013;145(6):1459-63
   PubMed Web of Science ®Google Scholar
• Strong SA, Koltun WA, Hyman NH, et al. Practice parameters for the surgical management of Crohn’s disease. Dis Colon Rectum 2007;50(11):1735-46
   PubMedGoogle Scholar
• Antunes O, Filippi J, Hébtuerne X, Pyrin-Biroulet L. Treatment algorithms in Crohn’s-up, down, or something else? Best Pract Res Clin Gastroenterol 2014;28(3):473-83
   PubMed Web of Science ®Google Scholar
• Cimzia [package insert]. UCB, Inc; Atlanta, GA: 2008
   Google Scholar
• Fossati G, Nesbitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol [abstract 807]. Presented at: American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course; 28 October – 2 November 2005; Hawaii, USA
   Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357(3):228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357(3):239-50
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105(7):1574-82
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Vavricka SR, Binke J, et al. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn’s disease population: results of the FACTS survery. Inflamm Bowel Dis 2010;16(6):933-8
   PubMedGoogle Scholar
• Vavricka SR, Schoepfer AM, Bansky G, et al. Efficacy and safety of certolizumab pegol in an unselected Crohn’s disease population: 26 week data of the FACTS II survey. Inflamm Bowel Dis 2011;17(7):1530-9
   PubMed Web of Science ®Google Scholar
• Sanborn WJ, Abreu MT, D’Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8(8):688-95
   PubMedGoogle Scholar
• Hanauer SB, Panes J, Colombel JF, et al. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease. Aliment Pharmcol Ther 2010;32(3):384-93
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31(1):92-101
   PubMed Web of Science ®Google Scholar
• Vermeire S, Abreu M, D’Haens G, et al. Efficacy and safety of certolizumab pegol in patients with active Crohn’s disease who previously lost response or were intolerant to infliximab: open-label induction results of the WELCOME study (abstract P- 0066). Presented at: 2008 Advances in Inflammatory Bowel Disease Clinical and Research Conference; 4-7 December 2008; Hollywood, FL, USA
   Google Scholar
• Danese S, Mocciaro F, Guidi L, et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn’s disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use (letter). Inflamm Bowel Dis 2008;14(8):1168-70
   PubMedGoogle Scholar
• Vermeire S, Collin B, Mitchev K, et al. Certolizumab pegol in patients with Crohn’s disease who failed treatment with other anti-TNFs: data from a compassionate use program [abstract P- 065]. Presented at: 2007 Advances in Inflammatory Bowel Disease Clinical and Research Conference; 6–9 December 2007; Aventura, FL, USA
   Google Scholar
• Hébtuerne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement in mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2013;62(2):201-8
   PubMedGoogle Scholar
• Danese S, Stefanelli T, Omodei P, et al. Successful treatment of fistulizing Crohn’s disease with certolizumab pegol. Inflamm Bowel Dis 2008;14(2):292-3
   PubMedGoogle Scholar
• Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remissions in patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8(7):600-9
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12(3):423-31
   PubMed Web of Science ®Google Scholar
• Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on. health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009;2:101-9
   PubMedGoogle Scholar
• Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneous administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn’s disease. Int J Colorectal Dis 2008;23(3):289-96
   PubMedGoogle Scholar
• Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECISE 2 study. Aliment Pharmcol Ther 2010;31(12):1276-85
   PubMedGoogle Scholar
• Feagan BG, Sandborn WJ, Wolf DC, et al. Randomized clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33(5):541-50
   PubMedGoogle Scholar
• Stidham RW, Lee TC, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther 2014;39(12):1349-62
   PubMed Web of Science ®Google Scholar
• Patil SA, Rustgi A, Langenberg P, Cross RK. Comparative effectiveness of anti-TNF agents for Crohn’s disease in a tertiary referral IBD practice. Dig Dis Sci 2013;58(1):209-15
   PubMed Web of Science ®Google Scholar
• Humira [package insert]. AbbVie, Inc; North Chicago, IL: 2002
   Google Scholar
• Fisher MD, Watson C, Fox KM, et al. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Curr Med Res Opin 2013;29(5):561-8
   PubMed Web of Science ®Google Scholar
• Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24(8):2229-40
   PubMed Web of Science ®Google Scholar
• Blume SW, Fox KM, Joseph G, et al. Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis in a pharmacy benefit management setting. Adv Ther 2013;30(5):517-27
   PubMedGoogle Scholar
• Park KT, Crandall WV, Fridge J, et al. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis 2014;20(5):946-51
   PubMedGoogle Scholar
• Certolizumab pegol. Red book online [database online]. Truven Health Analytics, Inc., Ann Arbor, MI; Updated periodically www.redbook.com/redbook/index.html [Accessed 21 June 2014]
   Google Scholar
• Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn’s disease in a commercially-insured setting. Am J Ther 2006;13(6):502-6
   PubMedGoogle Scholar
• Sussman DA, Kubiliun N, Mulani PM, et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis 2012;18(11):2043-55
   PubMedGoogle Scholar
• Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterol 2008;135(5):1493-9
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut 2011;60(7):930-6
   PubMed Web of Science ®Google Scholar
• Van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014;63(1):72-9
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis 2012;18(8):1523-30
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysis. Dig Dis Sci 2012;57(2):472-80
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005;353(18):1912-25
   PubMed Web of Science ®Google Scholar
• Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9(4):438-46
   PubMed Web of Science ®Google Scholar
• Tang DT, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn’s disease. Pharmacotheraphy 2012;32(6):515-26
   PubMed Web of Science ®Google Scholar
• Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2013;19(7):1528-33
   PubMed Web of Science ®Google Scholar